Savant Capital LLC Acquires 3,658 Shares of Medpace Holdings, Inc. $MEDP

Savant Capital LLC raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 56.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,176 shares of the company’s stock after buying an additional 3,658 shares during the quarter. Savant Capital LLC’s holdings in Medpace were worth $5,232,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. NewEdge Advisors LLC increased its holdings in shares of Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after buying an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after acquiring an additional 3,010 shares during the period. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Medpace during the second quarter valued at approximately $296,000. Finally, Truist Financial Corp boosted its position in Medpace by 10.2% during the 2nd quarter. Truist Financial Corp now owns 12,898 shares of the company’s stock valued at $4,048,000 after acquiring an additional 1,197 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Mizuho set a $660.00 price target on shares of Medpace in a report on Friday, January 9th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Truist Financial set a $555.00 price objective on Medpace in a report on Monday, October 27th. Finally, Barclays raised their price target on shares of Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $491.27.

Insider Activity at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO August J. Troendle sold 668 shares of Medpace stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the transaction, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 320,192 shares of company stock worth $192,909,762 over the last 90 days. Company insiders own 20.30% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $541.27 on Friday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The stock has a 50-day simple moving average of $580.60 and a 200-day simple moving average of $536.29. The stock has a market cap of $15.25 billion, a P/E ratio of 37.85, a P/E/G ratio of 1.89 and a beta of 1.42.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.